TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC
NCT07498595
·
clinicaltrials.gov ↗
EARLY_PHASE1
Phase
NOT_YET_RECRUITING
Status
50
Enrollment
OTHER
Sponsor class
Conditions
EGFR-TKI-resistant Non-Small Cell Lung Cancer
Interventions
DRUG:
TILs infusion
Sponsor
Tianjin Medical University General Hospital